Tags: FDA | Pfizer | disease | Drug

FDA Staff Shoots Down Pfizer's Rare Disease Drug

Tuesday, 22 May 2012 09:20 AM

U.S. drug reviewers recommended on Tuesday rejecting a Pfizer Inc drug because the data did not prove it worked well in treating a rare neurodegenerative disease.

The U.S. Food and Drug Administration staff reviewed the drug, tafamidis, ahead of an advisory panel of outside experts, which will vote on whether to recommend it for approval on Thursday. The FDA will make a final decision later, taking into account the panel's recommendation.

Tafamidis, which is already approved in Europe under the name Vyndaqel, is meant to treat familial amyloid polyneuropathy, a fatal condition that affects about 8,000 people worldwide, according to Pfizer.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
101
2012-20-22
Tuesday, 22 May 2012 09:20 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved